Citigroup’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Citigroup’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$2.68M	–	5835
2023 Q1	$2.68M	Buy	+25,000	New	+$2.88M	﹤0.01%	1825

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Citigroup's RXDX Position: Q2 2023 in Review

Citigroup sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 85,757 shares — an estimated $9.2M sold.

Citigroup first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $9.2M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Citigroup reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citigroup sold 85,757 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $9.2M.
Citigroup first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Citigroup's Prometheus Biosciences, Inc. Common Stock position peaked at $9.2M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.